Crossmark Global Holdings Inc. Buys 121 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Crossmark Global Holdings Inc. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,307 shares of the company’s stock after buying an additional 121 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Krystal Biotech were worth $362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech in the third quarter valued at $40,000. Values First Advisors Inc. purchased a new position in shares of Krystal Biotech in the 3rd quarter worth about $53,000. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 184.8% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after purchasing an additional 279 shares during the last quarter. Huntington National Bank raised its holdings in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Krystal Biotech by 242.4% in the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.2 %

Shares of NASDAQ KRYS opened at $154.81 on Monday. The firm’s fifty day moving average is $167.93 and its 200 day moving average is $181.02. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34. The company has a market cap of $4.45 billion, a price-to-earnings ratio of 87.46 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.67) earnings per share. Equities research analysts anticipate that Krystal Biotech, Inc. will post 3.03 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on KRYS. Chardan Capital reiterated a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).